Pharmaceutical Research and Manufacturers of America
Pharmaceutical Research and Manufacturers of America (PhRMA) is a 501(c)(6) trade association representing the country's leading biopharmaceutical researchers and biotechnology companies. Based in Washington, DC, PhRMA conducts effective advocacy for public policies that encourage the discovery of important new medicines for patients by biopharmaceutical research companies. The organization works with and on behalf of its member companies before governmental and regulatory bodies in the United States and throughout the world.
Financial Overview
From 2024 IRS Form 990-PF · View filing
Total Assets
$349.0M
-12.5% YoY
Annual Giving
$41.4M
+32.1% YoY
Grant Count
461
+24.6% YoY
Avg Grant Size
$90K
+6.1% YoY
Mission & Focus Areas
PhRMA's mission is to conduct effective advocacy for public policies that encourage the discovery of important new medicines for patients by biopharmaceutical research companies. The organization achieves this mission by advocating for:
- Broad patient access to safe and effective medicines through a free market, without government price controls
- Strong intellectual property incentives
- Transparent, efficient regulation and a free flow of information to patients
PhRMA is committed to working with stakeholders in Washington, across the country and around the world to expand patient access to safe and effective medicines, protect strong intellectual property incentives, and promote transparent, effective regulation.
Grantmaking
The PhRMA Foundation has expanded its 2026 awards program with industry support, reaching 65 early-career scientists. Recent award announcements include:
Ready to take the next step with Pharmaceutical Research and Manufacturers of America?
Geographic Focus
Where this funder awards grants
PhRMA operates in the United States and throughout the world, working with governmental and regulatory bodies internationally. The organization has a presence in multiple countries including India, Japan, China, Israel, and Egypt.
Grant Distribution by State
States
Cities
Financial History
Multi-year comparison from IRS filings
PhRMA (Trade Association)
2024:
- Revenue: $521M
- Expenses: $578M
- Total Assets: $349M
- Total Liabilities: $190M
2023:
- Revenue: $483,040,082
- Expenses: $426,549,040
- Total Assets: $210,928,967
2022:
- Revenue: $568,384,699
- Expenses: $574,376,853
- Assets: $286,234,000
Staffing
PhRMA employs approximately 254-295 people.
Tax Status
PhRMA is designated as a 501(c)(6) business league. Donations to this organization are not tax deductible. The organization has been tax-exempt since February 1959 (EIN: 53-0241211).
Notable Financial Items
According to its December 2024 tax filing, PhRMA provided first-class or charter travel to key employees or officers and reported conflict of interest transactions with interested parties.
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| Total Assets | $349,012,370 | $398,950,677 | $286,234,000 |
| Revenue | $521,348,217 | $483,040,082 | $568,384,699 |
| Expenses | $578,265,057 | $426,549,040 | $574,376,853 |
| Qualifying Distributions | — | — | — |
| Net Investment Income | $11,851,925 | $14,913,289 | $2,760,411 |
| Distributable Amount | — | — | — |
Giving Over Time
Total grant dollars and number of grants per year
Grant Insights
How this funder distributes its grants
Top Recipients
Top 10 recipients in 2024
Grant Size Distribution
250 grants across all recorded years
Giving History
Grant recipients and amounts by year
No grants recorded for .
Leadership & Key People
Leadership team and compensation from IRS filings
Stephen Ubl serves as CEO of PhRMA.
Compensation Overview
From 2024 IRS filing
From 2024 filing
| Name | Title | Hours | Compensation |
|---|---|---|---|
| Albert Bourla PHD | VICE CHAIR | 2 | — |
| Daniel O' Day | CHAIR | 2 | — |
| Paul Hudson | TREASURER | 2 | — |
| Stephen J Ubl | President & CEO | 37.5 | $5,935,826 |
| Alexander Hardy | DIRECTOR | 2 | — |
| ANTHONY MANCINI | DIRECTOR (THRU 08/24) | 2 | — |
| Ashley Magargee | DIRECTOR | 2 | — |
| Barry Greene | DIRECTOR | 2 | — |
| Bob Lojewski | DIRECTOR | 2 | — |
| Brad Bailey | DIRECTOR (AS OF 08/24) | 2 | — |
| Chris Boerner PHD | DIRECTOR | 2 | — |
| Chris ROUND | DIRECTOR (THRU 12/24) | 2 | — |
| Chris Viehbacher | DIRECTOR | 2 | — |
| David Loew | DIRECTOR | 2 | — |
| David Ricks | DIRECTOR | 2 | — |
| DOUGLAS L LANGA | DIRECTOR (THRU 12/24) | 2 | — |
| Emma Walmsley | DIRECTOR | 2 | — |
| Herve J Hoppenot | DIRECTOR | 2 | — |
| Jean-Christophe Tellier MD | DIRECTOR | 2 | — |
| Jean-Michel Boers | DIRECTOR | 2 | — |
| Jennifer Taubert | DIRECTOR | 2 | — |
| Julie Kim | DIRECTOR | 2 | — |
| Ken Keller | DIRECTOR | 2 | — |
| KEVIN C GORMAN PhD | DIRECTOR (THRU 09/24) | 2 | — |
| Kyle Gano PHD | DIRECTOR (AS OF 10/24) | 2 | — |
| MARK REISENAUER | DIRECTOR (THRU 04/24) | 2 | — |
| Michael Petroutsas | DIRECTOR (AS OF 02/24) | 2 | — |
| MYRTLE POTTER | DIRECTOR (THRU 03/24) | 2 | — |
| Richard F Pops | DIRECTOR | 2 | — |
| Robert A Bradway | DIRECTOR | 2 | — |
| Robert M Davis | DIRECTOR | 2 | — |
| Sebastian Guth PHD | DIRECTOR | 2 | — |
| Tarek Rabah | DIRECTOR | 2 | — |
| Tatsuyki Yasuno | DIRECTOR | 2 | — |
| Thomas Gibbs | DIRECTOR | 2 | — |
| Vasant Vas Narasimhan MD | DIRECTOR | 2 | — |
| James C Stansel | General Counsel & EVP Law, Secretary | 37.5 | $1,761,157 |
| Tracey Merchant | CFO & EVP, Administration | 37.5 | $1,340,588 |
| Elizabeth Carpenter | EVP, Policy/Research | 37.5 | $1,077,102 |
| Lori Reilly | COO | 37.5 | $2,547,833 |
| Renuka Iyer | EVP, Human Resources | 37.5 | $652,356 |
| Robert Zirkelbach II | EVP, Public Affairs | 37.5 | $1,190,211 |
| Shannon Monsif | EVP, Alliance | 37.5 | $1,115,048 |
| Steven Tilton | EVP, Federal Advocacy | 37.5 | $920,326 |
| Anne Pritchett | SVP, Policy/Research | 37.5 | $2,066,592 |
| Jay Taylor | EVP, International | 37.5 | $990,116 |
| Kenneth K McKay IV | SVP, State Advocacy | 37.5 | $935,523 |
| Michael Woody | SVP, Federal Advocacy | 37.5 | $1,175,941 |
| Scott LaGanga | EVP, State Advocacy | 37.5 | $1,199,864 |
| Jennifer Bryant | EVP, Policy/Research | 37.5 | $1,858,936 |
Recent News & Activity
Recent developments and announcements
The PhRMA Foundation continues to expand its research funding initiatives. Recent activities include:
PhRMA Foundation Awards $3.7M in 2026 Drug Discovery, Delivery, and Translational\Awarding $3.7M in 2026 Drug Discovery, Delivery, and Translational Medicine Fellowships and Grants
PhRMA Foundation Awards $3.7M in 2026 Drug Discovery, Delivery, and Translational\Honoring 9 researchers with 2026 Value Assessment and Health Outcomes Research Awards
PhRMA Foundation Honors 9 Researchers With 2026 Value Assessment and Health\Expanding 2026 awards with industry support to reach 65 early-career scientists
PhRMA Foundation Expands 2026 Awards With Industry Support, Reaching 65\Recognizing 6 clinical and translational science papers with Trainee Challenge Awards
PhRMA Foundation Awards $3.7M in 2026 Drug Discovery, Delivery, and Translational\Hosting informational webinars and Q&A sessions about research funding opportunities
The Foundation features researcher spotlights highlighting innovative work in areas such as therapeutic products for gastrointestinal symptoms and novel therapeutic targets for multiple sclerosis.
PhRMA Foundation Honors 9 Researchers With 2026 Value Assessment and Health\Related Funders
Similar funders by location and focus area
Demand Justice Initiative
WASHINGTON, DC
Assets
$7.6M
Grants
1
Total Given
$225K
American Academic Leadership Institute
WASHINGTON, DC
Assets
$3.6M
Grants
2
Total Given
$50K
Cnfa
WASHINGTON, DC
Assets
$18.3M
Grants
9
Total Given
$4.2M
Partnership for a Healthier America
WASHINGTON, DC
Assets
$10.8M
Grants
12
Total Given
$350K
Association of Schools of Allied Health
WASHINGTON, DC
Assets
$2.3M
Grants
2
Total Given
$60K
Fulcrum Foundation Inc
WASHINGTON, DC
Assets
$53K
Grants
10
Total Given
$13K
Data last updated April 2026. Sourced from IRS Form 990-PF filings. Research dossier generated April 2026.
What could you do with Pharmaceutical Research and Manufacturers of America on Grantable?
- Assess strategic fit with your organization
- Draft a tailored letter of inquiry
- Find open RFPs from this funder
- Monitor for new funding opportunities